An open-label phase I dose escalation expansion study of MGY825 in adult patients with advanced non-small cell lung cancer

Brief description of study

This study wants to figure out if a new medicine called MGY825 is safe and helpful for patients with advanced non-small cell lung cancer. They also want to learn how the body handles this medicine and if it can shrink tumors. The main aim is to make sure it's safe and useful for future treatments. They'll watch closely for any side effects, adjust the doses as needed, and see how it affects the patients overall. The study has two parts: first, they'll find the safest and most effective dose, and then they'll test it on different groups of patients. They're especially interested in patients with specific genetic changes (NFE2L2/KEAP1/CUL3) and certain enzyme levels because these things might affect how well the medicine works. The ultimate goal is to offer better treatments for those with advanced lung cancer who have already tried other options.


Clinical Study Identifier: s22-01322
ClinicalTrials.gov Identifier: NCT05275868
Principal Investigator: Vamsidhar Velcheti.
Other Investigators: Danny Perlaza, Samantha VanMaanen, Elka R Travis, Salman Rafi Punekar, Elaine Shum, Carol M Lee, Jessica Wang, James Newman, Gabrielle Fridman, Joshua K Sabari, Marissa Rybstein, David Mendoza, Melissa L Martinez, Jonathan B Kahn, Jeffrey G Schneider, Sally Lau, Natalia Cherkassky, Kirby Rodriguez.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.